Table 2.

Features of estrogen use among 222 AD patients and 222 nondemented control subjects

CharacteristicAD patients, n (%)Control subjects, n (%)p Value*
* p Value based on McNemar’s test for proportions.
† The information was missing for 12 case patients (6%) and 23 control subjects (10%).
Estrogen use, any duration33 (15)47 (21)0.08
Total dose of estrogen
None189 (85)175 (79)
≤20 mg7 (3)7 (3)0.92
21–500 mg7 (3)8 (4)0.71
>500 mg7 (3)9 (4)0.54
Duration of estrogen use
Never189 (85)175 (79)
<6 mo22 (10)25 (11)0.64
≥6 mo11 (5)22 (10)0.05
Form of estrogen
None189 (85)175 (79)
Oral only16 (7)29 (13)0.04
Topical only11 (5)11 (5)1.00
Oral and topical combined6 (3)7 (3)0.78